{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/54210"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/54210","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies","abstract":"'Smart' targeted drug carriers have long been sought after in the treatment of epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, relative to current clinical therapies (generally limited to surgery, radiation therapy, traditional chemotherapy, and EGF receptor inhibitors (EGFRIs)), of using such 'smart' targeted drug delivery systems. However, progress toward this goal has been challenged by the difficulty of creating a drug carrier that can autonomously detect and respond to tumor cells in the body. 'Smart' micron-size drug-encapsulating epidermal growth factor (EGF)-sensitive liposomes for EGF-overexpressing cancer therapies have been developed and studied. These drug-encapsulating liposomes remain inert until they are exposed to an abnormal concentration of EGF. As a drug delivery system, these drug-encapsulating liposomes could release pharmaceutical agents specifically in the immediate neighborhood of tumors overexpressing EGF, thereby maximizing the effective amount of drug received by the tumor while minimizing the effective systemic toxicity of the drug. Additionally, quantitative mathematical models were developed to characterize multiple critical rate processes (including drug leakage from drug-encapsulating liposomes and distribution of (drug-encapsulating) liposomes in blood vessels) associated i with (drug-encapsulating) liposomes in general.","abstract_html":"'Smart' targeted drug carriers have long been sought after in the treatment of epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, relative to current clinical therapies (generally limited to surgery, radiation therapy, traditional chemotherapy, and EGF receptor inhibitors (EGFRIs)), of using such 'smart' targeted drug delivery systems. However, progress toward this goal has been challenged by the difficulty of creating a drug carrier that can autonomously detect and respond to tumor cells in the body. 'Smart' micron-size drug-encapsulating epidermal growth factor (EGF)-sensitive liposomes for EGF-overexpressing cancer therapies have been developed and studied. These drug-encapsulating liposomes remain inert until they are exposed to an abnormal concentration of EGF. As a drug delivery system, these drug-encapsulating liposomes could release pharmaceutical agents specifically in the immediate neighborhood of tumors overexpressing EGF, thereby maximizing the effective amount of drug received by the tumor while minimizing the effective systemic toxicity of the drug. Additionally, quantitative mathematical models were developed to characterize multiple critical rate processes (including drug leakage from drug-encapsulating liposomes and distribution of (drug-encapsulating) liposomes in blood vessels) associated i with (drug-encapsulating) liposomes in general.","abstract_has_math":false,"creators":["Wong, Albert, S.M. Massachusetts Institute of Technology"],"institution":"Massachusetts Institute of Technology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Harvard University--MIT Division of Health Sciences and Technology.","school":null,"contributors":[],"advisors":["Klavs F. Jensen and Robert S. Langer."],"committee_chairs":[],"committee_members":[],"year":2009,"date_issued":"2009","date_published":"2009","updated_at":"2026-07-22T22:22:10Z","subjects":["Harvard University--MIT Division of Health Sciences and Technology."],"languages":["eng"],"rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"rights_urls":["http://dspace.mit.edu/handle/1721.1/7582"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1721.1/54210","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Klavs F. Jensen and Robert S. Langer."]},{"key":"dc:contributor.department","label":"Department","values":["Harvard University--MIT Division of Health Sciences and Technology."]},{"key":"dc:contributor.other","label":"Dc Contributor Other","values":["Harvard University--MIT Division of Health Sciences and Technology."]},{"key":"dc:creator","label":"Author","values":["Wong, Albert, S.M. Massachusetts Institute of Technology"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2010-04-26T19:18:56Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2010-04-26T19:18:56Z"]},{"key":"dc:date.issued","label":"Date","values":["2009"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Harvard University--MIT Division of Health Sciences and Technology."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://dspace.mit.edu/handle/1721.1/7582"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1721.1/54210"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2009.","This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.","Cataloged from PDF version of thesis.","Includes bibliographical references (p. 68-72)."]},{"key":"dc:description.abstract","label":"Abstract","values":["'Smart' targeted drug carriers have long been sought after in the treatment of epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, relative to current clinical therapies (generally limited to surgery, radiation therapy, traditional chemotherapy, and EGF receptor inhibitors (EGFRIs)), of using such 'smart' targeted drug delivery systems. However, progress toward this goal has been challenged by the difficulty of creating a drug carrier that can autonomously detect and respond to tumor cells in the body. 'Smart' micron-size drug-encapsulating epidermal growth factor (EGF)-sensitive liposomes for EGF-overexpressing cancer therapies have been developed and studied. These drug-encapsulating liposomes remain inert until they are exposed to an abnormal concentration of EGF. As a drug delivery system, these drug-encapsulating liposomes could release pharmaceutical agents specifically in the immediate neighborhood of tumors overexpressing EGF, thereby maximizing the effective amount of drug received by the tumor while minimizing the effective systemic toxicity of the drug. Additionally, quantitative mathematical models were developed to characterize multiple critical rate processes (including drug leakage from drug-encapsulating liposomes and distribution of (drug-encapsulating) liposomes in blood vessels) associated i with (drug-encapsulating) liposomes in general.","(cont.) These quantitative mathematical models provide a low-cost and rapid method for screening novel drug-encapsulating liposome compositions, configurations, and synthetic methods to identify liposome compositions, configurations, and synthetic methods that would deliver optimal performance. The results provide a stepping stone toward the development of EGF-sensitive liposomes for clinical use. More generally, they also present implications for future development of other targeted drug delivery vehicles."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["S.M."]},{"key":"dc:title","label":"Title","values":["Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies"]}]}],"canonical_facts":{"dc:contributor.advisor":["Klavs F. Jensen and Robert S. Langer."],"dc:contributor.department":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:contributor.other":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:creator":["Wong, Albert, S.M. Massachusetts Institute of Technology"],"dc:date.accessioned":["2010-04-26T19:18:56Z"],"dc:date.available":["2010-04-26T19:18:56Z"],"dc:date.issued":["2009"],"dc:description":["Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2009.","This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.","Cataloged from PDF version of thesis.","Includes bibliographical references (p. 68-72)."],"dc:description.abstract":["'Smart' targeted drug carriers have long been sought after in the treatment of epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, relative to current clinical therapies (generally limited to surgery, radiation therapy, traditional chemotherapy, and EGF receptor inhibitors (EGFRIs)), of using such 'smart' targeted drug delivery systems. However, progress toward this goal has been challenged by the difficulty of creating a drug carrier that can autonomously detect and respond to tumor cells in the body. 'Smart' micron-size drug-encapsulating epidermal growth factor (EGF)-sensitive liposomes for EGF-overexpressing cancer therapies have been developed and studied. These drug-encapsulating liposomes remain inert until they are exposed to an abnormal concentration of EGF. As a drug delivery system, these drug-encapsulating liposomes could release pharmaceutical agents specifically in the immediate neighborhood of tumors overexpressing EGF, thereby maximizing the effective amount of drug received by the tumor while minimizing the effective systemic toxicity of the drug. Additionally, quantitative mathematical models were developed to characterize multiple critical rate processes (including drug leakage from drug-encapsulating liposomes and distribution of (drug-encapsulating) liposomes in blood vessels) associated i with (drug-encapsulating) liposomes in general.","(cont.) These quantitative mathematical models provide a low-cost and rapid method for screening novel drug-encapsulating liposome compositions, configurations, and synthetic methods to identify liposome compositions, configurations, and synthetic methods that would deliver optimal performance. The results provide a stepping stone toward the development of EGF-sensitive liposomes for clinical use. More generally, they also present implications for future development of other targeted drug delivery vehicles."],"dc:description.degree":["S.M."],"dc:identifier.uri":["http://hdl.handle.net/1721.1/54210"],"dc:language.iso":["eng"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"dc:rights.uri":["http://dspace.mit.edu/handle/1721.1/7582"],"dc:subject":["Harvard University--MIT Division of Health Sciences and Technology."],"dc:title":["Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies"],"dc:type":["Thesis"]},"updated_at":"2026-07-22T22:22:10Z"}